Ibuprofen Kabi

Ibuprofen, the active ingredient in Ibuprofen Kabi, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an intravenous solution for intravenous use. It provides analgesic, antipyretic and anti‑inflammatory effects for the treatment of mild to moderate pain, fever, postoperative discomfort and musculoskeletal inflammation in adult patients.

GNH USA supplies Ibuprofen Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality through rigorous quality‑control procedures and provides technical support for safe clinical use.

Ibuprofen Kabi, an NSAID, reduces inflammation and pain by inhibiting cyclooxygenase enzymes.

- Mild to moderate pain: provides rapid analgesic relief in acute and chronic settings. - Fever: lowers elevated body temperature through antipyretic action. - Post‑operative pain: controls postoperative discomfort and facilitates recovery. - Musculoskeletal inflammation: diminishes swelling and improves mobility in conditions such as sprains or arthritis.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dyspepsia: discomfort or burning in the upper abdomen. - Headache: transient cranial pain. - Injection site reactions: erythema, pain or swelling at the infusion site. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Gastrointestinal bleeding: severe hemorrhage or ulceration. - Renal impairment: acute kidney injury or reduced function. - Severe hypersensitivity: anaphylaxis, angioedema, or skin rash. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Thrombocytopenia: marked reduction in platelet count.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Renal function: assess baseline creatinine and adjust use in renal impairment. - Hepatic function: monitor liver enzymes in patients with liver disease. - Cardiovascular risk: use the lowest effective dose in patients with hypertension or heart disease. - Gastrointestinal history: avoid in individuals with active peptic ulcer disease. - Concomitant anticoagulation: increase monitoring for bleeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Ibuprofen Kabi can alter the activity of several co‑administered medicines.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - ACE inhibitors: may reduce renal perfusion. - Lithium: elevated lithium levels. - Methotrexate: decreased clearance leading to toxicity. - Other NSAIDs: additive gastrointestinal and renal toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: potential for reduced renal function. - Antihypertensives: possible attenuation of blood‑pressure control. - SSRIs: heightened bleeding tendency. - Corticosteroids: increased risk of gastrointestinal ulceration. - Oral hypoglycemics: may affect glucose control.